

Press release
Lund 26 Jan 2024

Ground-breaking milestone in Head & Neck cancer treatment achieved

Scandinavian ChemoTech announces pivotal achievements when the Ethics Committee, at the University Hospital in Jodhpur, greenlights protocol amendment to the Head & Neck Cancer (HNC) study to include Tumour Specific Electroporation (TSE) in earlier curative lines and the first patients has been treated.

The approved protocol amendment positions TSE within the earlier curative lines of therapy for patients with head & neck cancer. It represents a paradigm shift in our field of medicine, bringing TSE to the forefront of curative interventions for these indications. This strategic move marks an unprecedented milestone, redefining the landscape of electroporation treatment for cancer and is poised to transform the way cancer treatment is approached by researchers and medical practitioners.

"Securing the approval in this clinical study is undeniably the most significant milestone our team has accomplished. If the results align with the experiences of physicians in India, Asia, and Africa, we stand a remarkable chance to influence the future of the global HNC market. The total valuation of the Indian HNC market for TSE treatment kits is estimated at around 160 million EUR." - says Mohan Frick CEO at Scandinavian ChemoTech

"We are thrilled by the Ethics Committee's approval of the protocol amendment for our 'Tumour Specific Electroporation' study. This is not only a testament to the scientific rigour behind our research but also a remarkable leap forward in cancer treatment. The inclusion of TSE in earlier curative lines for head and neck patients demonstrates our commitment to pioneering solutions that make a real impact on patients' lives." - says Dr Suhail Mufti, Medical Director at Scandinavian ChemoTech

For further information please contact:
Mohan Frick, CEO

Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se

Certified Adviser: Redeye AB, Phone: +46 (0)8 - 121 576 90
E-mail: certifiedadviser@redeye.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-01-2024 08:10 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.